CADL Stock Analysis: Candel Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 720m USD | 12M Return: 97.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 16.8M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 4.9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Candel Therapeutics (NASDAQ: CADL) is a U.S.-based, clinical-stage biopharmaceutical company headquartered in Needham, Massachusetts, that develops cancer immunotherapies. Its lead candidate, CAN-2409, is in Phase 2a trials for both prostate cancer and non-small cell lung cancer (NSCLC), while CAN-3110 is in a Phase 1b trial for recurrent high-grade glioma. The company also operates the enLIGHTEN Discovery Platform, which uses herpes simplex virus-based vectors and advanced analytics to design new viral immunotherapy candidates for solid tumors. Candel was originally incorporated in 2003 as Advantagene, Inc., adopted its current name in November 2020, and has been listed on NASDAQ since July 2021.
As a clinical-stage biotechnology company, Candel is focused on drug development rather than marketed products, a typical business model in which pre-revenue biotechs fund lengthy clinical programs through equity and partnership capital. Its use of engineered oncolytic viruses represents a niche within immuno-oncology aimed at selectively destroying tumor cells and stimulating a systemic immune response against the cancer.
- CAN-2409 Phase 2a prostate cancer trial data readout
- CAN-2409 NSCLC Phase 2a results advance immunotherapy pipeline
- CAN-3110 glioblastoma trial progress and enLIGHTEN platform expansion
- Cash burn and dilution risk as clinical-stage biotech without product revenue
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.25 > 0.02 and ΔFCF/TA 10.72 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.24 > 3% & CFO -47.7m > Net Income -54.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 28.05 > 1.5 & < 3 |
| Outstanding Shares: last quarter (62.4m) vs 12m ago 96.88% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 1.04%; Δ -1.04% > 0%) |
| Interest Coverage Ratio: -15.12 > 6 (EBIT TTM -51.0m / Interest Expense TTM 3.38m) |
| A: 0.94 (Total Current Assets 197.8m - Total Current Liabilities 7.05m) / Total Assets 201.9m |
| B: -1.18 (Retained Earnings -239.2m / Total Assets 201.9m) |
| C: -0.34 (EBIT TTM -51.0m / Avg Total Assets 148.9m) |
| D: 2.16 (Book Value of Equity 138.0m / Total Liabilities 63.9m) |
| Altman-Z'' = 2.30 = BBB |
As of July 08, 2026, the stock is trading at USD 9.85 with a total of 1,575,841 shares traded. Over the past week, the price has changed by -4.92%, over one month by +15.88%, over three months by +98.99% and over the past year by +97.39%.
Current recommended Stop Loss: 8.70 (which is 11.7% or 1.8 ATR below the current price).
Candel Therapeutics has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy CADL.
- StrongBuy: 3
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 20.3 | 106% |
P/E Forward = 43.4783
P/S = 1473.7131
P/B = 5.2181
Revenue TTM = 0.0 USD
EBIT TTM = -51.0m USD
EBITDA TTM = -50.3m USD
Long Term Debt = 47.5m USD (from longTermDebt, last quarter)
Short Term Debt = 453k USD (from shortTermDebt, last quarter)
Debt = 49.7m USD (corrected: LT Debt 47.5m + ST Debt 453k) + Leases 1.80m
Net Debt = -90.1m USD (calculated: Debt 49.7m - CCE 139.8m)
Enterprise Value = 630.1m USD (720.2m + Debt 49.7m - CCE 139.8m)
Interest Coverage Ratio = -15.12 (Ebit TTM -51.0m / Interest Expense TTM 3.38m)
EV/FCF = -12.61x (Enterprise Value 630.1m / FCF TTM -50.0m)
FCF Yield = -7.93% (FCF TTM -50.0m / Enterprise Value 630.1m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 749k) / Revenue TTM)
Tobins Q-Ratio = 3.12 (Enterprise Value 630.1m / Total Assets 201.9m)
Interest Expense / Debt = 6.79% (Interest Expense 3.38m / Debt 49.7m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -40.3m (EBIT -51.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 19.60 (Total Current Assets 197.8m / Total Current Liabilities 10.1m)
Debt / Equity = 0.36 (Debt 49.7m / totalStockholderEquity, last quarter 138.0m)
Debt / EBITDA = 1.79 (negative EBITDA) (Net Debt -90.1m / EBITDA -50.3m)
Debt / FCF = 1.80 (negative FCF - burning cash) (Net Debt -90.1m / FCF TTM -50.0m)
Total Stockholder Equity = 90.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -36.55% (Net Income -54.4m / Total Assets 201.9m)
RoE = -60.42% (Net Income TTM -54.4m / Total Stockholder Equity 90.1m)
RoCE = -37.11% (EBIT -51.0m / Capital Employed (Equity 90.1m + L.T.Debt 47.5m))
RoIC = -20.65% (negative operating profit) (NOPAT -40.3m / Invested Capital 195.3m)
WACC = 13.39% (E(720.2m)/V(770.0m) * Re(13.94%) + D(49.7m)/V(770.0m) * Rd(6.79%) * (1-Tc(0.21)))
Discount Rate = 13.94% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 91.11 | Cagr: 40.58%
[DCF] Fair Price = unknown (Cash Flow -50.0m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.32 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.26 | Chg30d=N/A | Revisions=+0% | Analysts=1
EPS next Quarter (2026-09-30): EPS=-0.26 | Chg30d=N/A | Revisions=+0% | Analysts=1
EPS current Year (2026-12-31): EPS=-0.87 | Chg30d=-13.42% | Revisions=+0% | GrowthEPS=+0.3% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=0.22 | Chg30d=+134.38% | Revisions=-25% | GrowthEPS=+125.2% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -25% (up=0, down=1)